Ramipril
Brand names: Tritace
Ramipril is an ACE inhibitor used for hypertension, heart failure, and cardiovascular and renal protection; this page focuses on its use in older people.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits angiotensin-converting enzyme, reducing angiotensin II formation and aldosterone, causing vasodilatation and lowering blood pressure and cardiac afterload.
Prescribing in practice
- In older people start at a low dose and uptitrate cautiously, as they are more prone to first-dose and symptomatic hypotension, acute kidney injury and hyperkalaemia, particularly with volume depletion, renovascular disease or concurrent NSAIDs or diuretics.
- Check renal function and potassium before starting and after dose changes; stop if there is a significant rise in creatinine or potassium.
- It is contraindicated in pregnancy and in those with a history of ACE-inhibitor angioedema.
Monitoring
Monitor blood pressure, renal function and serum potassium at baseline, after initiation and following each dose increase, especially in older patients.
Counselling the patient
- A dry cough can occur and may warrant switching to an alternative.
- Report dizziness, or swelling of the face, lips or tongue, urgently.
- Avoid over-the-counter anti-inflammatory painkillers without advice.
Evidence & guidelines
Landmark trials including HOPE established ramipril's cardiovascular benefit, and NICE supports ACE inhibitors across hypertension and heart failure with cautious titration in older adults.
Reference: NICE NG136 (Hypertension); NICE NG106 (Chronic Heart Failure); HOPE Trial; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5